Niagen Bioscience, Inc. (NAGE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 50M 100M 150M Q4 '17: 17.8M Q1 '18: 24.4M Q2 '18: 28M Q3 '18: 30M Q4 '18: 31.6M Q1 '19: 35M Q2 '19: 38.3M Q3 '19: 42.3M Q4 '19: 46.3M Q1 '20: 50.6M Q2 '20: 54.8M Q3 '20: 56.9M Q4 '20: 59.3M Q1 '21: 59.6M Q2 '21: 62M Q3 '21: 65.1M Q4 '21: 67.4M Q1 '22: 70M Q2 '22: 69.1M Q3 '22: 68.8M Q4 '22: 72M Q1 '23: 77.3M Q2 '23: 80.9M Q3 '23: 83.4M Q4 '23: 83.6M Q1 '24: 83.2M Q2 '24: 85.6M Q3 '24: 91.7M Q4 '24: 99.6M Q1 '25: 107.9M Q2 '25: 116.3M Q3 '25: 124.7M Q4 '25: 129.4M Q1 '26: 130.4M Q2 '26: 129.1M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

0 30M 60M 90M Q4 '16: 11M Q4 '16: 11.5M Q2 '17: 9.6M Q3 '17: 7.6M Q3 '17: 8.7M Q4 '17: 10.5M Q1 '18: 12M Q2 '18: 13.7M Q3 '18: 15.2M Q4 '18: 16.1M Q1 '19: 18.2M Q2 '19: 20.6M Q3 '19: 23M Q4 '19: 25.8M Q1 '20: 28.8M Q2 '20: 31.6M Q3 '20: 33.3M Q4 '20: 35.3M Q1 '21: 36.2M Q2 '21: 37.9M Q3 '21: 40M Q4 '21: 41.5M Q1 '22: 42.8M Q2 '22: 42M Q3 '22: 41.6M Q4 '22: 42.8M Q1 '23: 45.8M Q2 '23: 48.1M Q3 '23: 49.9M Q4 '23: 50.8M Q1 '24: 50.7M Q2 '24: 52.1M Q3 '24: 56.3M Q4 '24: 61.6M Q1 '25: 67.5M Q2 '25: 74M Q3 '25: 79.7M Q4 '25: 83.2M Q1 '26: 83.8M Q2 '26: 82.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Income TTM

-45M -30M -15M 0 15M 30M 45M Q4 '16: -1.3M Q4 '16: -2.3M Q2 '17: -4.5M Q3 '17: -7.5M Q3 '17: -9.8M Q4 '17: -16.4M Q1 '18: -23M Q2 '18: -28.3M Q3 '18: -33.7M Q4 '18: -33.2M Q1 '19: -33.1M Q2 '19: -32.4M Q3 '19: -30.7M Q4 '19: -31.3M Q1 '20: -28.8M Q2 '20: -25.3M Q3 '20: -22.6M Q4 '20: -19.9M Q1 '21: -21.3M Q2 '21: -23.2M Q3 '21: -27.8M Q4 '21: -27.1M Q1 '22: -27.4M Q2 '22: -28.3M Q3 '22: -22.5M Q4 '22: -18.6M Q1 '23: -12.9M Q2 '23: -8.8M Q3 '23: -6.9M Q4 '23: -5.6M Q1 '24: -4.4M Q2 '24: -2.3M Q3 '24: 447K Q4 '24: 7.7M Q1 '25: 13.2M Q2 '25: 16.7M Q3 '25: 19.3M Q4 '25: 16.3M Q1 '26: 13.1M Q2 '26: 10.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-45M -30M -15M 0 15M 30M 45M Q4 '16: -2.2M Q4 '16: -2.9M Q2 '17: -5.1M Q3 '17: -7.8M Q3 '17: -4.7M Q4 '17: -11.4M Q1 '18: -17.9M Q2 '18: -23.2M Q3 '18: -33.9M Q4 '18: -33.3M Q1 '19: -33.2M Q2 '19: -32.9M Q3 '19: -31.5M Q4 '19: -32.1M Q1 '20: -29.7M Q2 '20: -25.7M Q3 '20: -22.7M Q4 '20: -19.9M Q1 '21: -21.4M Q2 '21: -23.3M Q3 '21: -27.9M Q4 '21: -27.1M Q1 '22: -27.5M Q2 '22: -28.3M Q3 '22: -20.4M Q4 '22: -16.5M Q1 '23: -10.7M Q2 '23: -6.5M Q3 '23: -6.5M Q4 '23: -4.9M Q1 '24: -3.5M Q2 '24: -1.4M Q3 '24: 1.5M Q4 '24: 8.6M Q1 '25: 14.1M Q2 '25: 17.7M Q3 '25: 20.4M Q4 '25: 17.4M Q1 '26: 18.6M Q2 '26: 16M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 20M 40M 60M Q4 '16: 10.2M Q4 '16: 13.1M Q2 '17: 11M Q3 '17: 8.4M Q3 '17: 9.5M Q4 '17: 10.7M Q1 '18: 12.4M Q2 '18: 14.3M Q3 '18: 14.8M Q4 '18: 15.5M Q1 '19: 16.8M Q2 '19: 17.7M Q3 '19: 19.3M Q4 '19: 20.5M Q1 '20: 21.8M Q2 '20: 23.2M Q3 '20: 23.6M Q4 '20: 24M Q1 '21: 23.4M Q2 '21: 24.1M Q3 '21: 25.1M Q4 '21: 26M Q1 '22: 27.2M Q2 '22: 27M Q3 '22: 27.2M Q4 '22: 29.3M Q1 '23: 31.6M Q2 '23: 32.8M Q3 '23: 33.5M Q4 '23: 32.8M Q1 '24: 32.4M Q2 '24: 33.5M Q3 '24: 35.3M Q4 '24: 38M Q1 '25: 40.5M Q2 '25: 42.3M Q3 '25: 45M Q4 '25: 46.2M Q1 '26: 46.6M Q2 '26: 46.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow TTM

-27M -18M -9M 0 9M 18M 27M Q4 '16: -4M Q4 '16: -2.9M Q2 '17: -91.5K Q3 '17: -5.5M Q3 '17: -5.8M Q4 '17: -9.8M Q1 '18: -13.7M Q2 '18: -14.8M Q3 '18: -19.5M Q4 '18: -20.9M Q1 '19: -20M Q2 '19: -22.4M Q3 '19: -25M Q4 '19: -20.4M Q1 '20: -22.6M Q2 '20: -15.1M Q3 '20: -11.2M Q4 '20: -10.6M Q1 '21: -10.8M Q2 '21: -17.1M Q3 '21: -19.2M Q4 '21: -24.2M Q1 '22: -26M Q2 '22: -21.9M Q3 '22: -19.7M Q4 '22: -15.1M Q1 '23: -5.1M Q2 '23: 2M Q3 '23: 6.1M Q4 '23: 7.1M Q1 '24: 4.6M Q2 '24: 1.1M Q3 '24: 4.2M Q4 '24: 12.1M Q1 '25: 19.7M Q2 '25: 21.2M Q3 '25: 21.4M Q4 '25: 13.5M Q1 '26: 4.4M Q2 '26: 5.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-27M -18M -9M 0 9M 18M 27M Q3 '11: -2.4M Q4 '11: -3.5M Q4 '11: -4.2M Q1 '12: -9.1M Q2 '12: -11.5M Q3 '12: -11M Q4 '12: -10.1M Q1 '13: -6.2M Q2 '13: -3.9M Q3 '13: -3.1M Q4 '13: -4M Q1 '14: -4.7M Q2 '14: -3.9M Q3 '14: -4.1M Q1 '15: -2.7M Q2 '15: -2M Q1 '16: -2.6M Q2 '16: -4.9M Q3 '16: -5.2M Q4 '16: -5.2M Q4 '16: -4.4M Q2 '17: -1.7M Q3 '17: -7.1M Q3 '17: -7.3M Q4 '17: -11M Q1 '18: -14.9M Q2 '18: -16.9M Q3 '18: -21.1M Q4 '18: -22.2M Q1 '19: -21.4M Q2 '19: -22.8M Q3 '19: -25.4M Q4 '19: -21.2M Q1 '20: -23.1M Q2 '20: -15.7M Q3 '20: -11.7M Q3 '11 Q3 '12 Q4 '13 Q2 '15 Q4 '16 Q1 '18 Q2 '19 Q3 '20

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q2 '12: 91.4M Q3 '12: 98.4M Q1 '13: 97.9M Q2 '13: 99.8M Q3 '13: 101.3M Q1 '14: 106.1M Q2 '14: 106.2M Q3 '14: 106.6M Q2 '15: 35.7M Q2 '15: 107.2M Q3 '15: 35.8M Q4 '15: 107.4M Q2 '16: 37.5M Q3 '16: 37M Q4 '16: 37.9M Q4 '16: 37.9M Q2 '17: 38M Q3 '17: 42.1M Q3 '17: 47.6K Q4 '17: 51.2M Q3 '18: 55.1K Q2 '20: 60.9M Q3 '20: 61.7M Q1 '21: 64.2M Q2 '21: 68M Q3 '21: 68.2M Q1 '22: 68.3M Q2 '22: 68.3M Q3 '22: 68.3M Q1 '23: 74.8M Q2 '23: 75M Q3 '23: 75M Q1 '24: 75.2M Q2 '24: 75.6M Q3 '24: 77.8M Q1 '25: 83.2M Q2 '25: 86.2M Q3 '25: 86.6M Q1 '26: 84.6M Q2 '26: 82.5M Q3 '13 Q2 '15 Q4 '16 Q4 '17 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.60 -0.40 -0.20 0.00 0.20 0.40 0.60 Q1 '14: -0.05 Q2 '14: -0.06 Q3 '14: -0.06 Q1 '15: -0.08 Q2 '15: -0.09 Q1 '16: -0.06 Q2 '16: -0.04 Q3 '16: -0.03 Q4 '16: -0.06 Q4 '16: -0.08 Q2 '17: -0.14 Q3 '17: -0.21 Q3 '19: -0.56 Q4 '19: -0.56 Q1 '20: -0.51 Q2 '20: -0.43 Q3 '20: -0.38 Q4 '20: -0.33 Q1 '21: -0.35 Q2 '21: -0.37 Q3 '21: -0.43 Q4 '21: -0.40 Q1 '22: -0.39 Q2 '22: -0.40 Q3 '22: -0.28 Q4 '22: -0.23 Q1 '23: -0.15 Q2 '23: -0.09 Q3 '23: -0.09 Q4 '23: -0.07 Q1 '24: -0.05 Q2 '24: -0.02 Q3 '24: 0.01 Q4 '24: 0.10 Q1 '25: 0.17 Q2 '25: 0.21 Q3 '25: 0.24 Q4 '25: 0.20 Q1 '26: 0.21 Q2 '26: 0.18 Q2 '15 Q4 '16 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.